Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Sells $1,160,244.37 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONSGet Free Report) CEO Brett P. Monia sold 23,501 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $49.37, for a total value of $1,160,244.37. Following the transaction, the chief executive officer now owns 174,138 shares of the company’s stock, valued at approximately $8,597,193.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Ionis Pharmaceuticals Trading Down 2.4 %

IONS stock opened at $49.75 on Monday. The company has a current ratio of 6.39, a quick ratio of 6.33 and a debt-to-equity ratio of 4.06. Ionis Pharmaceuticals, Inc. has a 12-month low of $32.69 and a 12-month high of $54.44. The stock has a market cap of $7.14 billion, a price-to-earnings ratio of -17.33 and a beta of 0.46. The business’s 50-day moving average is $50.81 and its 200 day moving average is $46.09.

Ionis Pharmaceuticals (NASDAQ:IONSGet Free Report) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.02). The firm had revenue of $144.00 million during the quarter, compared to analyst estimates of $139.42 million. Ionis Pharmaceuticals had a negative return on equity of 90.50% and a negative net margin of 66.34%. On average, sell-side analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on IONS shares. Needham & Company LLC reiterated a “buy” rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Tuesday, December 19th. JPMorgan Chase & Co. lifted their price objective on Ionis Pharmaceuticals from $52.00 to $55.00 and gave the company a “neutral” rating in a research note on Thursday. Morgan Stanley lifted their price objective on Ionis Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. The Goldman Sachs Group lifted their price target on Ionis Pharmaceuticals from $25.00 to $28.00 and gave the company a “sell” rating in a research note on Friday, November 3rd. Finally, Stifel Nicolaus lifted their price target on Ionis Pharmaceuticals from $45.00 to $50.00 and gave the company a “hold” rating in a research note on Monday, December 18th. Three research analysts have rated the stock with a sell rating, five have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $49.80.

View Our Latest Stock Report on Ionis Pharmaceuticals

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Ionis Pharmaceuticals by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 12,806,023 shares of the company’s stock worth $566,411,000 after purchasing an additional 605,747 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Ionis Pharmaceuticals by 4.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,678,259 shares of the company’s stock worth $441,088,000 after purchasing an additional 521,564 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in shares of Ionis Pharmaceuticals by 10.1% during the 1st quarter. Clearbridge Investments LLC now owns 6,476,033 shares of the company’s stock worth $239,872,000 after purchasing an additional 593,051 shares during the last quarter. BVF Inc. IL boosted its holdings in shares of Ionis Pharmaceuticals by 11.1% during the 2nd quarter. BVF Inc. IL now owns 2,846,015 shares of the company’s stock worth $116,772,000 after purchasing an additional 285,254 shares during the last quarter. Finally, Camber Capital Management LP boosted its holdings in shares of Ionis Pharmaceuticals by 29.9% during the 2nd quarter. Camber Capital Management LP now owns 2,500,000 shares of the company’s stock worth $102,575,000 after purchasing an additional 575,000 shares during the last quarter. 93.86% of the stock is currently owned by institutional investors and hedge funds.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

See Also

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.